<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>While the use of radioimmunotherapy for <z:hpo ids='HP_0002665'>lymphoma</z:hpo> increases, the feasibility and efficacy of autologous stem cell transplant for subsequent relapse remains unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We report a 48-year-old male with transformed follicular mixed non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>After treatment with three different combination chemotherapy regimens, at relapse he received radioimmunotherapy with <z:chebi fb="60" ids="24859">iodine</z:chebi> (131)I tositumomab (anti-CD20), with very good response </plain></SENT>
<SENT sid="3" pm="."><plain>At later relapse, a second course of (131)I tositumomab was given unsuccessfully </plain></SENT>
<SENT sid="4" pm="."><plain>He underwent peripheral blood stem cell harvest, chemoradiotherapy conditioning and autologous transplantation with prompt engraftment and without significant complications </plain></SENT>
<SENT sid="5" pm="."><plain>He remains in complete remission with <z:mpath ids='MPATH_458'>normal</z:mpath> blood counts 25 months post autograft </plain></SENT>
</text></document>